![The F-35’s future: The world’s most advanced stealth fighter and what comes next [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/8477353.jpg?#)
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
A federal jury in Delaware has determined that Amgen violated U.S. antitrust laws by engaging in a bundling scheme that unfairly advantaged its cholesterol drug Repatha over Regeneron’s rival medicine Praluent.
A federal jury in Delaware has determined that Amgen violated U.S. antitrust laws by engaging in a bundling scheme that unfairly advantaged its cholesterol drug Repatha over Regeneron’s rival medicine Praluent.
